oxigene shares double on ovarian cancer trial results
don't you wish you had some shares now. Well, that's the same emotion actc shareholders are hoping for. But, given how cheap the shares are now, good news could bring this pps to 0.18 or higher, all despite the financial skeletons and dilution holding it down presently. With all the well known, prestigious eye surgeons and hospitals, and scientific board members and review by DMSB with privileged information in their hands, these folks would run for the hills rather than hurt their career reputations being associated with actc. this stock is risky but certainly no joke.